Senior Correspondent, London
Ben's Feed
Nov 18, 2014
Nov 18, 2014
Nov 18, 2014

AstraZeneca trumpets solo strength in cancer drugs post Pfizer struggle

LONDON (Reuters) – AstraZeneca (AZN.L: Quote, Profile, Research) touted an “industry-leading” line-up of hot new cancer drugs at an investor day on Tuesday, aiming to show it has a strong independent future after seeing off a $118 billion (75 billion pound) bid from Pfizer (PFE.N: Quote, Profile, Research) in May.

The company also brought forward the filing date for a new lung cancer pill, and said it could win between eight and 10 new approvals in 2015-2016 for drugs dealing with a wide range of diseases.

Nov 18, 2014
Nov 18, 2014

AstraZeneca trumpets standalone strength in drug development

LONDON (Reuters) – AstraZeneca, determined to show it has a strong independent future after seeing off a $118 billion bid from Pfizer in May, said it had made good progress in developing a pipeline of new drugs.

Flagging an “industry-leading” portfolio of immune-boosting cancer drugs, the company also brought forward the filing date for a new lung cancer pill and said it had the potential to win between eight and 10 new drug approvals in 2015-2016 across all disease areas.

Nov 17, 2014
Nov 17, 2014

World’s top drugmaker Novartis takes aim at tech

LONDON (Reuters) – Talent spotters from Novartis AG, charged with bringing new ideas into the organization, are casting their net beyond biotech into the wider pool of wearable, or even edible, technology.

It’s not that the world’s biggest drugmaker by sales wants to make the next smart watch. Rather, its researchers are seeking fresh ways to monitor exactly how the company’s medicines are working and being taken by patients.

Nov 17, 2014

Pfizer says deal makes it ‘competitive’ in immuno-oncology

LONDON (Reuters) – Pfizer’s (PFE.N: Quote, Profile, Research, Stock Buzz) deal to buy rights to a promising drug from Germany’s Merck KGaA (MRCG.DE: Quote, Profile, Research, Stock Buzz) will enable it to compete strongly in the fast-growing field of cancer immunotherapy, its research head said.

Some analysts have criticized Pfizer for being late to the hot new area of cancer research but Mikael Dolsten said on Monday his firm had now put together a strong portfolio of experimental immuno-oncology treatments.

Nov 17, 2014

Pfizer dampens Astra bid hopes with German Merck cancer deal

FRANKFURT/LONDON (Reuters) – Pfizer (PFE.N: Quote, Profile, Research) dampened investors’ expectations of a renewed bid for AstraZeneca (AZN.L: Quote, Profile, Research) on Monday by signing a major cancer drug deal with Germany’s Merck KGaA (MRCG.DE: Quote, Profile, Research), reducing the U.S. firm’s need for Astra’s products.

Merck will get an upfront payment of $850 million (544 million pounds) from the U.S. drugmaker for sharing rights to develop its experimental immunotherapy drug with Pfizer. It is also eligible for up to $2 billion in payments based on the medicine’s future success.

Nov 17, 2014

Pfizer dampens Astra bid hopes by signing German Merck cancer deal

FRANKFURT/LONDON (Reuters) – Pfizer (PFE.N: Quote, Profile, Research, Stock Buzz) punctured investor expectations of a renewed bid for AstraZeneca (AZN.L: Quote, Profile, Research, Stock Buzz) on Monday by signing a major cancer drug deal with Germany’s Merck KGaA (MRCG.DE: Quote, Profile, Research, Stock Buzz), reducing the U.S. firm’s need for Astra’s products.

Merck will get an upfront payment of $850 million from the U.S. drugmaker for sharing rights to develop its experimental immunotherapy drug with Pfizer. It is also is eligible for up to $2 billion in payments based on the medicine’s future success.

    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben